BioPharma Webinar - Latest Information on Quality Assessment of Next-Generation Modalities - 10/22 & 29 [Live Webinar]
The development of next-generation modalities, including nucleic acid medicines, AAV, and mRNA medicines, is rapidly expanding globally. In Japan, the government has set goals to expand the market size of the biopharmaceutical and regenerative medicine-related industries, leading to increased expectations and investments towards the practical application of next-generation modalities. On the other hand, guidelines for the characterization and quality evaluation of these next-generation modalities are still not clearly established domestically, and development companies may be gathering information on the latest scientific knowledge and analytical approaches.
In this webinar, we will introduce the latest analytical solutions for the characterization and quality evaluation of next-generation modalities from two approaches: mass spectrometry and light scattering detection. The content will provide insights into development and quality management based on market trends, so we encourage you to take this opportunity to participate.
Event Themes:
• October 22 (Thursday) 15:00–15:30
Quality evaluation of mRNA medicines interpreted through mass spectrometry
• October 29 (Thursday) 15:00–15:30
The forefront of aggregate and particle profiling and subvisible particle evaluation captured by light scattering detection

| Date and time | Thursday, Oct 22, 2026 ~ Thursday, Oct 29, 2026 03:00 PM ~ 03:30 PM To watch the live webinar, registration is required. Registration will be accepted until 12:00 on the day of the event. |
|---|---|
| Entry fee | Free |
Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration




